Phase 3 study on severe uncontrolled asthma (AST)2019-04-08T11:39:34+00:00

Project Description

Phase 3 study on severe uncontrolled asthma (AST)

Brief

Asthma is a lung chronic disease. involving the airways in the lungs. It is characterized by reversible obstruction and hyper-responsiveness of the airways with both of these physiological abnormalities occurring on a background of airway inflammation. Coughing, episodes of wheezing, chest tightness, and shortness of breath are the main symptoms.

R.G.L leads this international and competitive phase 3 study in Israel to prove the safety of therapeutic molecule in Asthma, as it has been mandated by a biotechnology company.

Goals

  • To find 2 medical centers with a high rate of patients recruitment,
  • To sign with all 2 centers a Clinical Trial Agreement and negotiate a budget per patient according to Sponsor’s guidelines and recommendations,
  • To obtain Local Ethical Committee approvals in the conduct of the Trial,
  • To obtain Ministry of Health’s approval in the conduct of the Trial for Israel, 
  • To recruit 100% of the recruitment patient potential (10 patients) on 12 months, 

Want To Work With Us?

WE WILL BE HAPPY TO WORK WITH YOU.

Contact Us